Elucidation of the molecular biological landscape for the development of novel therapies and diagnostics for solid tumors

Elucidation of the molecular biological landscape for the development of novel therapies and diagnostics for solid tumors - Elucidation of the molecular biological landscape for the development of novel therapies and diagnostics for solid tumors

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041008

Enrollment

1000

Registered

2020-07-06

Start date

2018-12-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Malignancies

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients over 18 years of age with histologically diagnosed malignancy 2. Usable tumor tissue samples collected between July 2011 and December 2021 are stored 3. Available blood samples collected between July 2011 and December 2021 are stored or new blood samples can be collected 4. (For National Cancer Institute cases) Blanket consent has been obtained in the National Center Biobank Network project. 5. Molecular profiling tests (gene panel tests, immunohistochemistry, etc.) are performed at the National Cancer Center Hospital East under the insurance reimbursement.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Molecular biological profiles of gene and protein expression and other genetic abnormalities in solid tumors	—

Countries

Japan

Contacts

Public ContactTakao Fujisawa

Department of the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East Translational Research Support Office, Division of Drug and Diagnostic Development Promotion

tafujisa@east.ncc.go.jp04-7133-1111

Outcome results